Li et al., 2021 - Google Patents
Recent progress on the mutations of SARS-CoV-2 spike protein and suggestions for prevention and controlling of the pandemicLi et al., 2021
View PDF- Document ID
- 8488190825852353909
- Author
- Li X
- Zhang L
- Chen S
- Ji W
- Li C
- Ren L
- Publication year
- Publication venue
- Infection, Genetics and Evolution
External Links
Snippet
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection has caused a global pandemic in the past year, which poses continuing threat to human beings. To date, more than 3561 mutations in the viral spike protein were identified, including 2434 mutations …
- 230000035772 mutation 0 title abstract description 100
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Recent progress on the mutations of SARS-CoV-2 spike protein and suggestions for prevention and controlling of the pandemic | |
| Bakhiet et al. | SARS-CoV-2: Targeted managements and vaccine development | |
| Lotfi et al. | COVID-19: Transmission, prevention, and potential therapeutic opportunities | |
| WO2017044507A3 (en) | Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection | |
| EP4632075A3 (en) | Method for reducing immunogenicity of rna | |
| EP4570264A3 (en) | Vaccine against porcine parvovirus | |
| PH12021550479A1 (en) | Dengue vaccine unit dose and administration thereof | |
| ATE547118T1 (en) | RECOMBINANT KOI HERPES VIRUS (KHV) OR CYPRINID HERPES VIRUS 3 (CYHV-3) AND VACCINE FOR PREVENTING DISEASE CAUSED BY KHV/CYHV-3 IN CYPRINUS CARPIO CARPIO OR CYPRINUS CARPIO KOI | |
| WO2017156511A8 (en) | Live attenuated zika virus vaccine | |
| HRP20150317T1 (en) | Vaccine Herb Peptides | |
| Castrucci et al. | The use of immunomodulators in the control of infectious bovine rhinotracheitis | |
| Harding et al. | The 12 deadliest viruses on earth | |
| Zhuang et al. | Immune responses to human respiratory coronaviruses infection in mouse models | |
| JP2017517561A5 (en) | ||
| MY189021A (en) | Peptides and uses therefor as antiviral agents | |
| MX2019013874A (en) | Peptides and uses therefor as antiviral agents. | |
| Tang et al. | Mutational escape prevention by combination of four neutralizing antibodies that target RBD conserved regions and stem helix | |
| Urbanek et al. | Influenza and stroke risk: a key target not to be missed? | |
| RU2005123050A (en) | SUPER ANTIGENIC FUSION PROTEINS AND THEIR USE | |
| Lin et al. | Nasal mucosa is much more susceptible than oral mucosa to infection of SARS‐CoV‐2 Omicron subvariants: Wearing nasal masks where facial masks cannot be used. | |
| Jeeninga et al. | The new influenza A (H1N1) pandemic | |
| PH12022550261A1 (en) | Methods for preventing dengue and hepatitis a | |
| 劉薏蓉 et al. | Peptides derived from SARS-CoV HR2 can act as an inhibitory agent of FCoV | |
| WO2025044920A3 (en) | New dev vectors for avian vaccines | |
| Rashid et al. | ROLE OF PHYTOCHEMICALS IN THE TREATMENT OF COVID 19: AN UPDATE |